147 related articles for article (PubMed ID: 32334842)
1. Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? No.
Labauge P
Rev Neurol (Paris); 2020 Jun; 176(6):494-496. PubMed ID: 32334842
[TBL] [Abstract][Full Text] [Related]
2. Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? Comment.
Ouallet JC
Rev Neurol (Paris); 2020 Jun; 176(6):500-504. PubMed ID: 32278541
[TBL] [Abstract][Full Text] [Related]
3. Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? Yes.
de Seze J; Bigaut K
Rev Neurol (Paris); 2020 Jun; 176(6):497-499. PubMed ID: 32265072
[TBL] [Abstract][Full Text] [Related]
4. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
[TBL] [Abstract][Full Text] [Related]
5. Predictors of relapse rate in MS clinical trials.
Held U; Heigenhauser L; Shang C; Kappos L; Polman C;
Neurology; 2005 Dec; 65(11):1769-73. PubMed ID: 16344520
[TBL] [Abstract][Full Text] [Related]
6. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
7. Laquinimod for multiple sclerosis.
He D; Han K; Gao X; Dong S; Chu L; Feng Z; Wu S
Cochrane Database Syst Rev; 2013 Aug; (8):CD010475. PubMed ID: 23922214
[TBL] [Abstract][Full Text] [Related]
8. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
9. Mitoxantrone for multiple sclerosis.
Martinelli Boneschi F; Vacchi L; Rovaris M; Capra R; Comi G
Cochrane Database Syst Rev; 2013 May; (5):CD002127. PubMed ID: 23728638
[TBL] [Abstract][Full Text] [Related]
10. Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis.
Gava G; Bartolomei I; Costantino A; Berra M; Venturoli S; Salvi F; Meriggiola MC
Fertil Steril; 2014 Jul; 102(1):116-22. PubMed ID: 24794311
[TBL] [Abstract][Full Text] [Related]
11. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
12. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.
Beiki O; Frumento P; Bottai M; Manouchehrinia A; Hillert J
JAMA Neurol; 2019 Jun; 76(6):665-671. PubMed ID: 30882868
[TBL] [Abstract][Full Text] [Related]
13. [Influence of acute aggravations on the development of long-term handicap in relapsing remitting multiple sclerosis: a clinical study in 99 patients].
Gaillard N; Fabro-Perray P; Faillie JL; Le Bayon A; Castelnovo G; Dupeyron A; Froger J; Pelissier J; Labauge P
Rev Neurol (Paris); 2007 Jan; 163(1):72-81. PubMed ID: 17304175
[TBL] [Abstract][Full Text] [Related]
14. Multiple Sclerosis: Epidemiologic, Clinical, and Therapeutic Aspects.
Vidal-Jordana A; Montalban X
Neuroimaging Clin N Am; 2017 May; 27(2):195-204. PubMed ID: 28391781
[TBL] [Abstract][Full Text] [Related]
15. Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: a longitudinal population-based evaluation.
Veugelers PJ; Fisk JD; Brown MG; Stadnyk K; Sketris IS; Murray TJ; Bhan V
Mult Scler; 2009 Nov; 15(11):1286-94. PubMed ID: 19965558
[TBL] [Abstract][Full Text] [Related]
16. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
17. Demographic and clinical profile of Multiple Sclerosis in Kashmir: A short report.
Zahoor I; Asimi R; Haq E; Yousuf Wani I
Mult Scler Relat Disord; 2017 Apr; 13():103-106. PubMed ID: 28427689
[TBL] [Abstract][Full Text] [Related]
18. Glatiramer acetate for multiple sclerosis.
La Mantia L; Munari LM; Lovati R
Cochrane Database Syst Rev; 2010 May; (5):CD004678. PubMed ID: 20464733
[TBL] [Abstract][Full Text] [Related]
19. Disease modifying drugs modulate endogenous secretory receptor for advanced glycation end-products, a new biomarker of clinical relapse in multiple sclerosis.
Sternberg Z; Sternberg D; Drake A; Chichelli T; Yu J; Hojnacki D
J Neuroimmunol; 2014 Sep; 274(1-2):197-201. PubMed ID: 25064498
[TBL] [Abstract][Full Text] [Related]
20. Initiation of first disease-modifying treatment for multiple sclerosis patients in the Czech republic from 2013 to 2016: Data from the national registry ReMuS.
Horakova D; Rockova P; Jircikova J; Dolezal T; Vachova M; Hradilek P; Valis M; Sucha J; Martinkova A; Ampapa R; Grunermelova M; Stetkarova I; Stourac P; Mares J; Dufek M; Kmetova E; Adamkova J; Hrnciarova T
Mult Scler Relat Disord; 2019 Oct; 35():196-202. PubMed ID: 31400559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
